These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. All That Glitters is Not Gold in Vedolizumab Therapy for Patients With Inflammatory Bowel Diseases and Primary Sclerosing Cholangitis. Roda G; Lleo A; Danese S; Aghemo A Clin Gastroenterol Hepatol; 2020 Jan; 18(1):51-53. PubMed ID: 31323379 [No Abstract] [Full Text] [Related]
7. Letter: vedolizumab drug levels in cord and maternal blood in women with inflammatory bowel disease-authors' reply. Mahadevan U; Vermeire S; Lasch K; Abhyankar B; Bhayat F; Blake A; Dubinsky M Aliment Pharmacol Ther; 2018 Aug; 48(3):388-389. PubMed ID: 29998501 [No Abstract] [Full Text] [Related]
8. Vedolizumab in IBD/PSC: A Case for Careful Vigilance? Jones F; Doherty GA J Crohns Colitis; 2019 Sep; 13(10):1237-1238. PubMed ID: 31560065 [No Abstract] [Full Text] [Related]
9. Letter: tricky reactions to switch back from subcutaneous to intravenous vedolizumab in inflammatory bowel disease patients-authors' reply. Volkers A; Straatmijer T; Duijvestein M; Löwenberg M; van der Meulen A; D'Haens G Aliment Pharmacol Ther; 2023 Mar; 57(6):743-744. PubMed ID: 36821751 [No Abstract] [Full Text] [Related]
10. Letter: the addition of an immunosuppressant in patients with unsatisfactory response to vedolizumab-Authors' reply. Strik AS; D'Haens GR Aliment Pharmacol Ther; 2018 Apr; 47(7):1041-1042. PubMed ID: 29512914 [No Abstract] [Full Text] [Related]
11. Letter: choosing between ustekinumab and vedolizumab in anti-TNF refractory Crohn's disease-the devil is in the detail. Authors' reply. Alric H; Amiot A; Carbonnel F; Meyer A Aliment Pharmacol Ther; 2020 Aug; 52(3):563-564. PubMed ID: 32656831 [No Abstract] [Full Text] [Related]
12. Editorial: vedolizumab in inflammatory bowel diseases-less is more? Authors' reply. Danese S; Subramaniam K; Van Zyl J; Adsul S Aliment Pharmacol Ther; 2021 Feb; 53(3):445-446. PubMed ID: 33428255 [No Abstract] [Full Text] [Related]
13. Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. Nordenvall C; Bergquist A Aliment Pharmacol Ther; 2018 Feb; 47(3):441-442. PubMed ID: 29314129 [No Abstract] [Full Text] [Related]
14. Letter: vedolizumab or a second anti-TNF-no difference in efficacy for primary biologic failures with IBD. Authors' reply. Rundquist S; Sachs MC; Eriksson C; Olén O; Montgomery S; Halfvarson J Aliment Pharmacol Ther; 2021 May; 53(9):1046-1047. PubMed ID: 33831234 [No Abstract] [Full Text] [Related]
16. Vedolizumab: a novel medical intervention in the treatment of primary sclerosing cholangitis. Westerveld D; Grajo J; Beattie L; Glover S BMJ Case Rep; 2017 May; 2017():. PubMed ID: 28501828 [No Abstract] [Full Text] [Related]
17. Editorial: achievements and unresolved questions in improving the pharmacokinetics of vedolizumab in adolescents with inflammatory bowel disease-authors' reply. Colman RJ; Minar P Aliment Pharmacol Ther; 2023 Mar; 57(5):567-568. PubMed ID: 36786467 [No Abstract] [Full Text] [Related]
18. Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis. Olmedo Martín RV; Amo Trillo V; González Grande R; Jiménez Pérez M Rev Esp Enferm Dig; 2017 Sep; 109(9):659-662. PubMed ID: 28724302 [TBL] [Abstract][Full Text] [Related]
19. Editorial: biologic therapies for primary sclerosing cholangitis-more disappointment than promise? Ma C; Kotze PG Aliment Pharmacol Ther; 2018 Sep; 48(5):576-577. PubMed ID: 30156325 [No Abstract] [Full Text] [Related]
20. Sclerosing Cholangitis in Children and Adolescents. Mieli-Vergani G; Vergani D Clin Liver Dis; 2016 Feb; 20(1):99-111. PubMed ID: 26593293 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]